Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25841
Title: Impact of inflammatory bowel disease and azathioprine on long-term outcomes after liver transplantation for primary sclerosing cholangitis.
Austin Authors: Peverelle, Matthew R ;De Cruz, Peter P ;Paleri, Sarang;Gow, Paul J 
Affiliation: Gastroenterology and Hepatology
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Victorian Liver Transplant Unit
Issue Date: 11-Feb-2021
metadata.dc.date: 2021
Publication information: Liver Transplantation 2021; online first: 21 February
Abstract: We read with interest the multicentre retrospective study by Irlès-Depé et al1 reporting the impact of inflammatory bowel disease (IBD) on long-term outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC). In their series PSC-IBD patients were found to have similar rates of death, recurrent PSC (rPSC) and malignancy as patients with isolated PSC. Moreover azathioprine (AZA) exposure was associated with increased mortality, an association which may have been due to an era effect.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25841
DOI: 10.1002/lt.26009
PubMed URL: 33569894
Type: Journal Article
Subjects: Mortality
Recurrent primary sclerosing cholangitis
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Apr 23, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.